泰和诚医疗上涨6.79%，报5.842美元/股，总市值2898.39万美元

Core Viewpoint - Taihe Cheng Medical (CCM) experienced a stock price increase of 6.79%, reaching $5.842 per share, with a total market capitalization of $28.9839 million as of August 26 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]